Webinar
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
Your Choice of 3 Available Sessions: May 21 - 22, 2025
May 21, 2025 | 1:00 – 1:45 PM ET
May 22, 2025 | 12:00 – 12:45 (UTC +8:00) – Asia/Shanghai
May 22, 2025 | 12:00 – 12:45 CET – Europe/Berlin
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies?
In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations. However, products with robust clinical differentiation or superiority can achieve price premiums over benchmarks.
Looking ahead, a recent policy to establish a Category C drug list is energizing the pharma industry, potentially providing coverage through government-guided commercial insurance for high-cost, innovative products not included in the NRDL.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will evaluate the impact of the value-rating system on NRDL negotiations, explore successful outcomes across therapeutic areas and introduce potential commercial pathways to inform strategic go-to-market planning for novel therapies.
Key Topics
- Overview of the 2024 China NRDL update: Changes, trends and outcomes
- Case studies across oncology, rare diseases and chronic conditions: Learnings from successful products
- Introduce the Category C and potential commercial access in the future
- Recommendation and outlook for future China pricing and access opportunities
